In addition, in BrCa patients who didn’t receive any chemotherapies, high expression PRDX1 (HR = 1.22, 95% CI: 1.03–1.44, P = 0.019), PRDX4 (HR = 1.37, 95% CI: 1.16–1.62, P < 0.001), PRDX6 (HR = 1.19, 95% CI: 1.00–1.40, P = 0.044) and low expression of PRDX3 (HR = 0.84, 95% CI: 0.71–1.00, P = 0.043) were associated with worse RFS. The gene discussed is PRDX1; the disease is invasive breast carcinoma.